Vertex Pharmaceuticals Reaches New 1-Year High at $99.00 (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX)’s share price reached a new 52-week high on Friday , AnalystRatings.Net reports. The company traded as high as $99.00 and last traded at $98.80, with a volume of 1,300,800 shares. The stock had previously closed at $98.03.
Several analysts have recently commented on the stock. Analysts at Goldman Sachs raised their price target on shares of Vertex Pharmaceuticals to $109.00 in a research note on Wednesday, June 25th. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, June 25th. They now have a $136.00 price target on the stock, up previously from $103.00. Finally, analysts at Sanford C. Bernstein raised their price target on shares of Vertex Pharmaceuticals from $65.00 to $107.00 in a research note on Wednesday, June 25th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $100.41.
The stock has a 50-day moving average of $75.69 and a 200-day moving average of $74.81. The company’s market cap is $23.336 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.65) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter last year, the company posted $0.03 earnings per share. Vertex Pharmaceuticals’s revenue was down 63.9% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals will post $-2.88 EPS for the current fiscal year.
In other Vertex Pharmaceuticals news, Director Elaine Ullian sold 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $95.21, for a total value of $476,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.